Position in ABVX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$11,770,989
New position
Shares Held
88,331
first reported quarter
Ownership
0.101%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#81
of 302 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ABVX
reported options exposure · as of Jun 30, 2026CallValue
$3,877,866
CallShares
29,100
PutValue
$16,657,500
PutShares
125,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026TORONTO DOMINION BANK holds $769,395,513 across 60 Biotechnology names. ABVX ranks #13 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
2,165,846 | $176,668,057 | |
| 2 | CELC |
Celcuity Inc.
|
1,258,758 | $131,691,261 | |
| 3 | STOK |
Stoke Therapeutics, Inc.
|
3,173,258 | $103,829,001 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
181,432 | $97,419,912 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
85,391 | $42,416,270 | |
| 6 | TARS |
Tarsus Pharmaceuticals, Inc.
|
510,253 | $32,115,323 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
48,783 | $30,418,151 | |
| 8 | NGNE |
Neurogene Inc.
|
681,337 | $21,428,048 |
All Filings in ABVX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16,657,500 | 125,000 | Put | Defined | 2026-08-14 | |
| 2026-06-30 | $11,770,989 | 88,331 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $3,877,866 | 29,100 | Call | Defined | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||